Skip to main content

Table 4 Data of patients entering the Phase B of the trial

From: A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk

Parameters

Amlodipine 10 mg

Amlodipine 10 mg + ASA 100 mg

Baseline

3 months

Baseline

3 months

N

54

52

56

55

Sex (M/F)

25/29

24/28

29/27

28/27

Smokers (M/F)

4/3

4/3

5/3

5/3

SBP (mmHg)

153.7 ± 9.1

134.8 ± 6.1°

154.2 ± 9.2

134.2 ± 5.9°

DPB (mmHg)

95.1 ± 5.2

82.5 ± 3.2°

96.8 ± 5.7

82.2 ± 3.1°

Hs-CRP (mg/l)

2.0 ± 0.8

1.6 ± 0.5*

2.0 ± 0.8

1.3 ± 0.4°^

ADN (μg/ml)

5.1 ± 1.1

6.0 ± 1.5*

5.3 ± 1.2

6.8 ± 1.9°^

TNF-α (pg/ml)

2.5 ± 0.8

2.0 ± 0.6*

2.2 ± 0.7

1.7 ± 0.4°^

IL-1β (pg/ml)

0.5 ± 0.8

0.5 ± 0.3

0.5 ± 0.4

0.3 ± 0.2*

MPO (ng/ml)

775.2 ± 219.5

728.1 ± 217.3*

774.2 ± 216.2

661.2 ± 112.3°^

sCDL40 (pg/ml)

1252.8 ± 118.9

1198.4 ± 99.7*

1268.5 ± 118.2

958.3 ± 82.4°^

  1. Data are expressed as mean ± standard deviation.
  2. M males, F females, Hs-CRP high sensitivity C-reactive protein, ADN adiponectin, TNF-α tumor necrosis factor-α, IL-1β interleukin-1β, MPO myeloperoxidase, sCDL40 soluble CD40 ligand.
  3. * p < 0.05 vs baseline.
  4. ° p < 0.01 vs baseline.
  5. ^ p < 0.05 vs amlodipine.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840